

Summary of Analysis Sets
(All Participants Randomized)

	Placebo n (%)	Xanomeline line Low Dose n (%)	Xanomeline line High Dose n (%)
Participants in Population	86	84	84
Participants included in ITT population	86 (100.0)	84 (100.0)	84 (100.0)
Participants included in efficacy population	79 (91.9)	81 (96.4)	74 (88.1)
Participants included in safety population	86 (100.0)	84 (100.0)	84 (100.0)